


# Immunogenicity of biopharmaceuticals

## Springer - Toxic Effects of Immunogenicity to Biopharmaceuticals



Description: -

-  
Product safety -- Law and legislation -- United States  
Consumer protection -- Law and legislation -- United States  
U.S. Consumer Product Safety Commission -- Appropriations and expenditures  
Pharmaceutical biotechnology  
Biopharmaceutics -- Immunology  
Immunological tolerance  
Immunogenicity of biopharmaceuticals

-  
Neue wissenschaftliche Bibliothek, 21. Geschichte  
Biotechnology (Arlington, Va.) -- v. 8.  
Biotechnology : pharmaceutical aspects -- v. 8  
Immunogenicity of biopharmaceuticals

Notes: Includes bibliographical references and index.

This edition was published in 2008



Filesize: 28.64 MB

Tags: #Immunotoxicity #and #Immunogenicity #of #Biopharmaceuticals: #Design #Concepts #and #Safety #Assessment

### Toxic Effects of Immunogenicity to Biopharmaceuticals

Neutralizing antibodies have a clear effect on efficacy and may also be responsible for toxicity if they obliterate the endogenous protein.

### Immunogenicity of biopharmaceuticals in laboratory animals

The loss of carbohydrate could expose areas of the molecule that are not normally seen by the human immune system; however, all patient antibodies bind to the fully glycosylated molecule, making this an unlikely explanation. American College of Rheumatology position statement: biosimilars.

### Biotechnology: Pharmaceutical Aspects: Immunogenicity of Biopharmaceuticals (Hardcover)

Thus, it is important to have an assay life cycle management process in place, which monitors assay performance over time and in different clinical indications.

### Biotechnology: Pharmaceutical Aspects: Immunogenicity of Biopharmaceuticals (Hardcover)

While the correlate of protection linking immunogenicity to risk of disease or carriage is not straightforward and varies between serotypes, immunogenicity data is the basis for licensure of new PCV products. The primary issue of concern for the safety of these agents is the potential for immunogenicity. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.

---

## Related Books

- [Popper e levoluzionismo](#)
- [Transport Policy-Theory and Practice.](#)
- [Dosri aurat ki mut.](#)
- [Study of the indigent/uninsured pursuant to SJR 298 of 1997 - report of the Joint Commission on Heal](#)
- [Of the visual area of the cerebral cortex, and its relation to eye movements](#)